Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)
H. Rosing, W. W. Ten Bokkel Huinink, R. van Gijn, R. F. M. Rombouts, A. Bult, J. H. BeijnenVolume:
24
Language:
english
Pages:
9
DOI:
10.1007/bf03190013
Date:
March, 1999
File:
PDF, 795 KB
english, 1999